VCYT News and Press, Veracyte Inc. From 02/21/23

Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, after market close. The consensus EPS Estimate is -$0.08 (+46.7% Y/Y) and the consensus Revenue Estimate is $74.92M (+11.3% Y/Y). Over the last 1 year, VCYT has beaten EPS est...

- Decipher Prostate test improves risk-stratification to help reduce under- and over-treatment - Veracyte, Inc . (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) dem...

Additional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier Veracyte, Inc . (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Sympo...

Summary Veracyte has a broad diagnostics offering that spans across multiple domains of complex disease. We are most attracted to its prostatic biopsy segment, obtained through its acquisition of Decipher Bio in FY21. Here, we examined this offering in-line with additional names in ...

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general...

Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-...

Findings published in Frontiers in Endocrinology were derived from analyses of Veracyte’s comprehensive thyroid nodule database of whole transcriptome sequencing Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in Frontiers in Endocrinology provid...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. It's an area that is expanding wildly. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...